https://www.selleckchem.com/pr....oducts/elsubrutinib.
The pharmaceutical industry is continuing to face high research and development (RD) costs and low overall success rates of clinical compounds during drug development. There is an increasing demand for development and validation of healthy or disease-relevant and physiological human cellular models that can be implemented in early-stage discovery, thereby shifting attrition of future therapeutics to a point in discovery at which the costs are significantly lower. There needs to be a paradigm shift in the early drug discovery p
Like
Comment
Share
